It can be hard to value a company at its inflection point.
The sequencer maker registers a profitable quarter thanks to a financial artifact.
The sequencer maker scales the wall of worry created by its competitor.
The sequencer maker highlights its new machine at the American Society of Human Genetics.
What goes up must come down.
A closer look at gene sequencing stocks -- and how you could score a double helix of gains
Healthcare stocks with plenty of potential -- and low share prices
A terrifying new cancer study out of Johns Hopkins Medicine confirms a suspicion some researchers have harbored all along.
A full human genome can now be sequenced for $1,000. That's still a little pricey for mass adoption, but Illumina and Pacific Biosciences could bring the cost down even further -- opening up the genomics floodgates.
What investors need to know about Pacific Biosciences' third quarter performance.